New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
CRISPR Therapeutics AG
CRSP
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

4B

Biotechnology

Next Earning date - 04 Nov 2024

4B

Biotechnology

Next Earning date - 04 Nov 2024

49.71USD
Shape2.35 ( 4.96%)
favorite-chart

Relative Strenght

15
favorite-chart

Volume Buzz

55%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

45%

Quote Panel

Shape
Updated October 28, 2024
1W 3.48 % 1M 5.81 % 3M -15.03 % 1Y 27.69 %

Key Metrics

Shape
  • Market Cap

    4.23B


  • Shares Outstanding

    85.17M


  • Share in Float

    81.47M


  • Dividende

    0


  • Earning Date

    04 Nov 2024


  • Price Target

    49.71


  • Average Volume

    1.10M


  • Beta

    1.672


  • Range

    38.158-91.1


  • Industry

    Biotechnology


  • Website

    https://www.crisprtx.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

21.06x

P/S Ratio

2.13x

P/B Ratio

0.1

Debt/Equity

-132.2%

Net Margin

$-3.2

EPS

How CRSP compares to sector?

P/E Ratio

Relative Strength

Shape

CRSP

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$258M

Shape49746%

2025-Revenue

$5.62

Shape-277%

2025-EPS

$102M

Shape30%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Wolfe Research

initialise

Previous: Not converted

2024-02-15

Now: Peer Perform

Cantor Fitzgerald

downgrade

Previous: Overweight

2023-10-17

Now: Neutral

Citigroup

upgrade

Previous: Neutral

2023-08-17

Now: Buy

Cantor Fitzgerald

initialise

Previous: Not converted

2023-04-13

Now: Overweight

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-2.24
vs -1.67

Q4.22

arrow
arrow

N/A

-1.41
vs -1.84

Q1.23

arrow
arrow

N/A

-0.67
vs -2.32

Q2.23

arrow
arrow

N/A

-0.98
vs -2.40

Q3.23

arrow
arrow

N/A

-1.41
vs -2.24

Q4.23

arrow
arrow

+178%

1.1
vs -1.41

Q1.24

arrow
arrow

N/A

-1.43
vs -0.67

Q2.24

arrow
arrow

N/A

-1.49
vs -0.98

Q3.24

arrow
arrow

N/A

-1.42
vs -1.41

Q4.24

arrow
arrow

N/A

-1.34
vs 1.1

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

-71%

94K  vs 329K

Q4.22

arrow
arrow

-100%

6K  vs 12.3M

Q1.23

arrow
arrow

+56080%

100M  vs 178K

Q2.23

arrow
arrow

+44204%

70M  vs 158K

Q3.23

arrow
arrow

-100%

NA  vs 94K

Q4.23

arrow
arrow

+3333233%

200M  vs 6K

Q1.24

arrow
arrow

-99%

504K  vs 100M

Q2.24

arrow
arrow

-99%

517K  vs 70M

Q3.24

arrow
arrow

NA

6.6M  vs NA

Q4.24

arrow
arrow

-86%

28.7M  vs 200M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-9%

-0.09
vs -0.09

Q4.22

arrow
arrow

-6%

-0.06
vs -0.09

Q1.23

arrow
arrow

-3%

-0.03
vs -0.06

Q2.23

arrow
arrow

-4%

-0.04
vs -0.03

Q3.23

arrow
arrow

-6%

-0.06
vs -0.04

Q4.23

arrow
arrow

+5%

0.05
vs -0.06

Q1.24

arrow
arrow

-6%

-0.06
vs 0.05

Q2.24

arrow
arrow

-6%

-0.06
vs -0.06

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

464

464
vs 460

1%

Q4.22

arrow
arrow

426

426
vs 464

-8%

Q1.23

arrow
arrow

405

405
vs 426

-5%

Q2.23

arrow
arrow

452

452
vs 405

12%

Q3.23

arrow
arrow

436

436
vs 452

-4%

Q4.23

arrow
arrow

514

514
vs 436

18%

Q1.24

arrow
arrow

517

517
vs 514

1%

Q2.24

arrow
arrow

478

478
vs 517

-8%

Earnings Growth

Latest News